Questions? Call 800-624-6242 About | Ordering | New Menu | Items in cart [0] SEARCH

PAPERBACK price:$43.50 add to cart Rights & Permissions Free PDF Access Sign in to download PDF book and chapters Free Resources PDF SUMMARY Display this book on your site! Related Titles Adverse Effects of Vaccines: Evidence and Causality Priorities for the National Vaccine Plan Other Related Titles New Vaccine Development: Establishing Priorities: Volume II, Diseases of Importance in Developing Countries (1986) Board on Population Health and Public Health Practice (BPH) Citation Manager Export the bibliographic data for this book in your chosen format Web Search Builder Use this book's key terms to search within this book, across our collection, or across the Web. Skim This Chapter Skim this chapter and use this chapter's key terms to search within this book. Reference Finder Paste in your own text to find books that relate to your topic. Citation Manager . "Appendix K: Contents to Volume I." New Vaccine Development: Establishing Priorities: Volume II, Diseases of Importance in Developing Countries. Washington, DC: The National Academies Press, 1986. Please select a format: Page 423   E-mail Share on facebook Facebook Share on delicious Delicious Share on stumbleupon Stumble Share on twitter Twitter More Sharing ServicesMore The following HTML text is provided to enhance online readability. Many aspects of typography translate only awkwardly to HTML. Please use the page image as the authoritative form to ensure accuracy. Appendix K Contents to Volume I Vaccine candidates for the following pathogens and diseases were evaluated in Volume 1 of the committee’s report: Bordetella pertussis Coccidioidomycosis Cytomegalovirus Hemophilus influenzae type b Hepatitis A virus Hepatitis B virus Herpes simplex viruses 1 and 2 Herpesvirus varicellae Influenza viruses A and B Neisseria gonorrhoeae Parainfluenza viruses Respiratory syncytial virus Rotavirus Streptococcus group B Page 423 Front Matter (R1-R16) 1. Summary (1-18) 2. Priority Setting for Health-Related Investments: A Review of Methods (19-29) 3. Overview of the Analytic Approach (30-43) 4. Comparison of Disease Burdens (44-62) 5. Predictions of Vaccine Development (63-75) 6. Assessing the Likely Utilization of New Vaccines (76-81) 7. Calculation and Comparison of the Health Benefits and Differential Costs Associated with Candidate Vaccines (82-105) 8. Additional Issues in the Selection of Priorities for Accelerated Vaccine Development (106-120) 9. Findings, Conclusions, and Recommendations (121-142) Appendix A: Selection of Vaccine Candidates for Accelerated Development (143-148) Appendix B: The Burden of Disease Resulting from Acute Respiratory Illness (149-158) Appendix C: The Burden of Disease Resulting from Diarrhea (159-169) Appendix D-1: The Prospects for Immunizing Against Dengue Virus (170-177) Appendix D-2: The Prospects for Immunizing Against Escherichia coli (178-185) Appendix D-3: The Prospects for Immunizing Against Hemophilus influenzae Type b (186-196) Appendix D-4: The Prospects for Immunizing Against Hepatitis A Virus (197-207) Appendix D-5: The Prospects for Immunizing Against Hepatitis B Virus (208-222) Appendix D-6: The Prospects for Immunizing Against Japanese Encephalitis Virus (223-240) Appendix D-7: The Prospects for Immunizing Against Mycobacterium leprae (241-250) Appendix D-8: The Prospects for Immunizing Against Neisseria meningitidis (251-266) Appendix D-9: The Prospects for Immunizing Against Parainfluenza Viruses (267-274) Appendix D-10: The Prospects for Immunizing Against Plasmodium spp. (275-286) Appendix D-11: The Prospects for Immunizing Against Rabies Virus (287-298) Appendix D-12: The Prospects for Immunizing Against Respiratory Syncytial Virus (299-307) Appendix D-13: The Prospects for Immunizing Against Rotavirus (308-318) Appendix D-14: The Prospects for Immunizing Against Salmonella typhi (319-328) Appendix D-15: The Prospects for Immunizing Against Shigella spp. (329-337) Appendix D-16: The Prospects for Immunizing Against Streptococcus Group A (338-356) Appendix D-17: The Prospects for Immunizing Against Streptococcus pneumoniae (357-375) Appendix D-18: The Prospects for Immunizing Against Vibrio cholerae (376-389) Appendix D-19: The Prospects for Immunizing Against Yellow Fever (390-402) Appendix E: Questionnaire for Assessing Morbidity-Mortality Trade-Offs (403-411) Appendix F: Technical Notes (412-412) Appendix G: Biographical Notes on Committee Members (413-417) Appendix H: Additional Sources of Advice to the Committee (418-419) Appendix I: Contents of Supplement to Volume II (420-420) Appendix J: Preface to Volume I (421-422) Appendix K: Contents to Volume I (423-423) Index (424-432)

Below are the first 10 and last 10 pages of uncorrected machine-read text (when available) of this chapter, followed by the top 30 algorithmically extracted key phrases from the chapter as a whole.
Intended to provide our own search engines and external engines with highly rich, chapter-representative searchable text on the opening pages of each chapter. Because it is UNCORRECTED material, please consider the following text as a useful but insufficient proxy for the authoritative book pages.

Do not use for reproduction, copying, pasting, or reading; exclusively for search engines.

OCR for page 423
New Vaccine Development: Establishing Priorities, Volume II, Diseases of Importance in Developing Countries Appendix K Contents to Volume I Vaccine candidates for the following pathogens and diseases were evaluated in Volume 1 of the committee’s report: Bordetella pertussis Coccidioidomycosis Cytomegalovirus Hemophilus influenzae type b Hepatitis A virus Hepatitis B virus Herpes simplex viruses 1 and 2 Herpesvirus varicellae Influenza viruses A and B Neisseria gonorrhoeae Parainfluenza viruses Respiratory syncytial virus Rotavirus Streptococcus group B

Representative terms from entire chapter:

type hepatitis